Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY) Short Interest Update

Key Points

• Sandoz Group AG saw a significant decline in short interest, dropping 28.8% from 67,400 shares to 48,000 shares as of August 31st.
• Jefferies Financial Group downgraded Sandoz Group from a "strong-buy" rating to a "hold," with an average rating of "Hold" from analysts.
• The company’s stock performance shows a current trading price of $58.77, with a 1-year low of $35.61 and a high of $63.72.

Sandoz Group AG Sponsored ADR (OTCMKTS:SDZNY - Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 48,000 shares, a decline of 28.8% from the August 15th total of 67,400 shares. Approximately 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 39,600 shares, the days-to-cover ratio is presently 1.2 days. Based on an average daily trading volume, of 39,600 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.0% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Jefferies Financial Group downgraded Sandoz Group from a "strong-buy" rating to a "hold" rating in a research report on Friday, August 8th. Three research analysts have rated the stock with a Hold rating, According to MarketBeat, the company has an average rating of "Hold".

Sandoz Group Stock Performance

Shares of OTCMKTS:SDZNY opened at $58.77 on Tuesday. The business's 50 day simple moving average is $59.31 and its 200 day simple moving average is $50.61. Sandoz Group has a 1 year low of $35.61 and a 1 year high of $63.72. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.24 and a quick ratio of 0.79.

About Sandoz Group

Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.